1. Home
  2. ENTA vs CIK Comparison

ENTA vs CIK Comparison

Compare ENTA & CIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • CIK
  • Stock Information
  • Founded
  • ENTA 1995
  • CIK 1987
  • Country
  • ENTA United States
  • CIK United States
  • Employees
  • ENTA N/A
  • CIK N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • CIK Finance/Investors Services
  • Sector
  • ENTA Health Care
  • CIK Finance
  • Exchange
  • ENTA Nasdaq
  • CIK Nasdaq
  • Market Cap
  • ENTA 154.0M
  • CIK 156.6M
  • IPO Year
  • ENTA 2013
  • CIK N/A
  • Fundamental
  • Price
  • ENTA $5.27
  • CIK $2.83
  • Analyst Decision
  • ENTA Buy
  • CIK
  • Analyst Count
  • ENTA 4
  • CIK 0
  • Target Price
  • ENTA $17.25
  • CIK N/A
  • AVG Volume (30 Days)
  • ENTA 194.0K
  • CIK 115.4K
  • Earning Date
  • ENTA 05-20-2025
  • CIK 01-01-0001
  • Dividend Yield
  • ENTA N/A
  • CIK 9.03%
  • EPS Growth
  • ENTA N/A
  • CIK N/A
  • EPS
  • ENTA N/A
  • CIK N/A
  • Revenue
  • ENTA $66,590,999.00
  • CIK N/A
  • Revenue This Year
  • ENTA N/A
  • CIK N/A
  • Revenue Next Year
  • ENTA N/A
  • CIK N/A
  • P/E Ratio
  • ENTA N/A
  • CIK N/A
  • Revenue Growth
  • ENTA N/A
  • CIK N/A
  • 52 Week Low
  • ENTA $4.09
  • CIK $2.50
  • 52 Week High
  • ENTA $17.24
  • CIK $3.19
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 45.38
  • CIK 53.58
  • Support Level
  • ENTA $4.96
  • CIK $2.81
  • Resistance Level
  • ENTA $6.23
  • CIK $2.83
  • Average True Range (ATR)
  • ENTA 0.33
  • CIK 0.03
  • MACD
  • ENTA -0.01
  • CIK 0.01
  • Stochastic Oscillator
  • ENTA 24.41
  • CIK 83.33

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations, and individuals.

Share on Social Networks: